Y-Intercept (HK)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Y-Intercept (HK)’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-434,531	Closed	-$3.3M	–	1542
2025 Q3	$3.3M	Buy	434,531 +98,436	+29%	+$820K	0.08%	362
2025 Q2	$3.01M	Buy	336,095 +194,230	+137%	+$1.81M	0.07%	422
2025 Q1	$1.06M	Buy	141,865 +73,242	+107%	+$591K	0.07%	384
2024 Q4	$516K	Sell	68,623 -14,500	-17%	-$110K	0.03%	707
2024 Q3	$632K	Sell	83,123 -6,229	-7%	-$47.3K	0.04%	660
2024 Q2	$552K	Buy	+89,352	New	+$493K	0.03%	767
2022 Q4	–	Sell	-29,226	Closed	-$368K	–	1003
2022 Q3	$368K	Buy	+29,226	New	+$376K	0.04%	637
2022 Q1	–	Sell	-11,042	Closed	-$153K	–	721
2021 Q4	$153K	Buy	+11,042	New	+$146K	0.04%	527
2021 Q3	–	Sell	-10,737	Closed	-$170K	–	649
2021 Q2	$170K	Buy	+10,737	New	+$146K	0.04%	544
2021 Q1	–	Sell	-12,579	Closed	-$94K	–	625
2020 Q4	$94K	Buy	+12,579	New	+$64.8K	0.04%	482

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Y-Intercept (HK)'s BCRX Position: Q4 2025 in Review

Y-Intercept (HK) sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 434,531 shares — an estimated $3.3M sold.

Y-Intercept (HK) first reported a position in BCRX in Q4 2020 and held it in 10 quarters. The position peaked at $3.3M in Q3 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Y-Intercept (HK) reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Y-Intercept (HK) sold 434,531 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $3.3M.
Y-Intercept (HK) first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Y-Intercept (HK)'s BioCryst Pharmaceuticals position peaked at $3.3M in Q3 2025.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.